Sinovac’s COVID-19 vaccine induces quick immune response – … – Thomson Reuters Foundation

* Sinovac releases results from Phase I/II vaccine trials
* Sinovac’s CoronaVac appears safe and well tolerated
* Late-stage trials to determine vaccine efficacy ongoing (Adds comments from Brazil in last paragraph)
By Miyoung Kim and Roxanne Liu
SINGAPORE/BEIJING, Nov 18 (Reuters) – Sinovac Biotech’s experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results…

Click here to view the original article.